Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.60
Bid: 9.50
Ask: 10.00
Change: -0.025 (-0.26%)
Spread: 0.50 (5.263%)
Open: 9.45
High: 9.60
Low: 9.45
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of share options and Directors' dealings

23 Nov 2016 16:21

RNS Number : 9836P
e-Therapeutics plc
23 November 2016
 

23 November 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Grant of share options and Directors' dealings

 

Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total of 10,310,000 ordinary shares of 0.1p each to certain executive directors and other employees (the "Optionholders"). The Optionholders are entitled to exercise their options in three tranches (as set out below) on or after the date specified below, if, at the time of exercise, the prevailing market price of the Company's ordinary shares is not less than the price set out below (the "Exercise Price"). Optionholders will be required to pay the Exercise Price to exercise their options.

Number of shares under option Exercise Price Exercise Date

3,436,666 16.76p 23 November 2018

3,436,667 20.95p 23 November 2018

3,436,667 25.14p 23 November 2019

Details of the individual options granted to executive directors are set out below:

Director Number of shares under option

Steve Medlicott 2,000,000

Sean Nicolson 750,000

The options referred to above are otherwise subject to the Rules of the Company's 2013 Performance Share Plan. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Steve Medlicott

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Exercise price(s)

Volume(s)

 

£0.1676

666,666

 

 

£0.2095

666,667

 

 

£0.2514

666,667

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 2,000,000 options over ordinary shares

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

         

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Sean Nicolson

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

Exercise Price(s)

Volume(s)

 

£0.1676

250,000

 

 

£0.2095

250,000

 

 

£0.2514

250,000

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 750,000

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLRLTLVFIR
Date   Source Headline
12th Feb 20134:08 pmRNSDirector/PDMR Shareholding
11th Feb 20133:38 pmRNSDirector/PDMR Shareholding
11th Feb 20137:00 amBUSe-Therapeutics to raise £40 million to advance lead cancer drug and exploit network pharmacology platform
8th Jan 20131:07 pmRNSHolding(s) in Company
18th Dec 20127:00 amBUSClinical Trial Update (ETS2101)
14th Nov 20123:30 pmRNSDirector/PDMR Shareholding
8th Nov 20126:01 pmRNSDirector/PDMR Shareholding
26th Oct 201210:25 amRNSDirector/PDMR Shareholding
23rd Oct 20125:23 pmRNSDirector/PDMR Shareholding
22nd Oct 20127:00 amBUSInterim Results for the six months ended 31 July 2012
2nd Oct 20128:57 amRNSDirector/PDMR Shareholding
25th Sep 20124:19 pmRNSDirector/PDMR Shareholding
12th Sep 20127:00 amBUSe-Therapeutics starts second phase I cancer trial of ETS2101
4th Sep 201211:00 amRNSNotice of Interim Results
6th Aug 20122:25 pmRNSAdditional Listing and Directors' Shareholdings
2nd Aug 20123:35 pmRNSAdditional Listing
31st Jul 20121:06 pmRNSResult of AGM
18th Jul 20125:14 pmRNSHolding(s) in Company
6th Jul 20122:08 pmBUSDirector/PDMR Shareholding
29th Jun 20121:03 pmRNSAnnual Financial Report
19th Jun 20127:00 amBUSe-Therapeutics' ETS2101 enters phase I clinical trial in brain cancer
22nd May 20127:03 amBUSe-Therapeutics' Preliminary Results for the Year Ended 31 January 2012
10th May 20127:00 amRNSNotice of Results
4th May 20126:00 pmRNSDirector/PDMR Shareholding
17th Apr 20123:55 pmRNSChange of Registered Office
29th Mar 20127:00 amBUSPhase I clinical trials of cancer drug ETS2101 approved by regulators
14th Mar 20125:59 pmRNSDirector/PDMR Shareholding
27th Feb 20127:00 amBUSPrime Minister Opens e-Therapeutics' Drug Discovery Centre near Oxford
8th Feb 20122:00 pmBUSe-Therapeutics to Present at The 14th Annual BIO CEO & Investor Conference
7th Feb 20128:41 amRNSHolding(s) in Company
6th Feb 20127:00 amBUSDirectorate Change
9th Jan 20122:00 pmBUSe-Therapeutics outlines goals for 2012 and announces presentation at Biotech Showcase Conference
30th Nov 20113:45 pmRNSDirector/PDMR Shareholding
27th Oct 201110:21 amRNSDirector/PDMR Shareholding
19th Oct 20117:00 amRNSInterim Results for the six months to 31 July 2011
26th Sep 20117:00 amRNSPatent for 'Power Behind the Throne'
21st Sep 20119:00 amRNSNotice of Interim Results
12th Sep 20111:06 pmRNSResult of AGM
17th Aug 20114:19 pmRNSDirector/PDMR Shareholding
15th Aug 20112:16 pmRNSDirector/PDMR Shareholding
9th Aug 201112:40 pmRNSDirector/PDMR Shareholding
28th Jul 201110:00 amRNSAnnual Financial Report
28th Jul 20117:30 amRNSDirector/PDMR Shareholding
25th Jul 20117:00 amRNSPreliminary Results and Business Update
29th Jun 20112:38 pmRNSNotice of Results
13th Jun 20117:00 amRNSDirectorate Change
6th Jun 20114:34 pmRNSAdditional Listing
24th May 20116:30 pmRNSDirector/PDMR Shareholding
23rd May 20115:59 pmRNSDirector/PDMR Shareholding
15th Mar 20112:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.